Chief Executive Officer and Managing Director, Percheron Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| CEO | Kazia Therapeutics Limited | Wholesale Investor (Thu 14 Nov 2019), Wholesale Investor (Tue 29 Oct 2019), Wholesale Investor (Tue 15 Jan 2019) |
| Chief Executive Officer and Managing Director | Percheron Therapeutics | Biotech Dispatch, Wholesale Investor |
Stories naming Dr James Garner. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.
Profile of Percheron Therapeutics, an ASX-listed biotech led by Dr James Garner, developing HMBD-002 against the VISTA protein to treat cancers that resist PD-1 immunotherapy, with Phase 2 trials planned for 2026.
Kazia Therapeutics reviews its 2019 clinical trial data read-outs at its AGM and recalls a share placement that strengthened its balance sheet and brought new institutional investors onto its register.
Kazia Therapeutics' chief executive discussed the biotech's recent four-million-dollar raise, ovarian cancer trial data, and a trans-Tasman award win during an interview in CommSec's executive series.
Kazia Therapeutics confirmed it received an R&D tax rebate from the Australian Taxation Office for the 2018 financial year, with funds earmarked for its clinical programs.